
RoslinCT to Join Manufacturing Network for CRISPR-Based Therapy
UK’s RoslinCT, a cell and gene therapy contract development and manufacturing organization, will be part of the Vertex Pharmaceuticals global network producing the CRISPR-based therapy exa-cel, which will be used for treatment of sickle cell disease and transfusion-dependent beta thalassemia.